An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
Justin G. Julander, James F. Demarest, Ray Taylor, Brian B. Gowen, Dennis M. Walling, Amanda Mathis, Y.S. Babu
Abstract
Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models of viral disease associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever viruses. In many cases, the compound is more efficacious in animal models than cell culture activity would predict. Based on favorable data from in vivo animal studies, galidesivir has recently undergone evaluation in several phase I clinical trials, including against severe acute respiratory syndrome coronavirus 2, and as a medical countermeasure for the treatment of Marburg virus disease.